Metabolic Syndrome and Depression – Clinical Relations
Authors:
M. Zeman 1; R. Jirák 2; A. Žák 1; M. Jáchymová 1; M. Vecka 1; E. Tvrzická 1; B. Staňková 1; M. Dušejovská 1
Authors place of work:
IV. interní klinika 1. LF UK a VFN, Praha
1; Psychiatrická klinika, centrum pro Alzheimerovu chorobu a Katedra psychiatrie IPVZ, Praha
2
Published in the journal:
Čas. Lék. čes. 2008; 147: 75-80
Category:
Review Article
Summary
The occurrence of both obesity and type 2 diabetes mellitus is rapidly increasing; according to WHO data, this can be considered as a worldwide epidemic. The obesity is one of the components of metabolic syndrome, the cluster of several risk factors of atherosclerosis such as dyslipidemia, hypertension, impaired glucose homeostasis, pro-thrombotic state and subclinical inflammation. The importance of the metabolic syndrome is confirmed by findings of the several times increased risk of both the type 2 diabetes mellitus and cardiovascular disease. Similarly, as in the case of obesity and diabetes, the incidence and prevalence of depressive disorder are still increasing and depressive disorder belongs to the most important causes of disability. The interrelations between depressive disorder and diabetes are known for a long time. Diabetics very often suffer from depression and vice versa, the depressive disorder is a significant risk factor of type 2 diabetes mellitus development and worsens the survival of diabetics. Those relationships have been recently intensively studied. Our paper reviews genetic, nutritional, metabolic and hormonal factors, contributing to the above mentioned syndrome.
Key words:
metabolic syndrome, diabetes mellitus type 2, genetic polymorphisms, oxidative stress, hyperhomocysteinemia, n-3 polyunsaturated fatty acids.
Zdroje
1. Eckel, R. H., Grundy, S. M., Zimmet, P. Z.: The metabolic syndrome. Lancet, 2005, 365, s. 1415–1428.
2. Bloomgarden, Z. T.: Definitions of the insulin resistance syndrome. Diabetes Care, 2004, 27, s. 824–830.
3. Okosun, I. S., Liao, Y., Rotimi, C. N. et al.: Abdominal obesity and clustering of multiple factors in metabolic syndrome in White, Black and Hispanic Americans. Ann. Epidemiol., 2000, 10, s. 263–270.
4. Athyros, V. G., Ganotakis, E. S., Elisaf, M., Mikhailidis, D. P.: The prevalence of the metabolic syndrome using the National Cholesterol Educational Program and International Diabetes Federation definitions. Curr. Med. Res. Opin., 2005, 8, s. 1157–1159.
5. Nestler, E. J., Barrot, M., DiLeone, R. J. et al.: Neurobiology of depression. Neuron, 2002, 34, s. 13–25.
6. Vaidya V.A., Duman R. S.: Depression-emerging insights from neurobiology. Br. Med. Bull., 2001, 57, s. 61–79.
7. Rugulies R.: Depression as a predictor for coronary heart disease. A review and meta-analysis. Am. J. Prev. Med., 2002, 23, s. 51–61.
8. Eaton W. W., Armenian H., Gallo J. et al.: Depression and risk for onset of type II diabetes: a prospective population-based study. Diabetes Care. 1996, 19, s. 1097–1102.
9. Zhang, X., Norris, S. L., Gregg, E. W. et al.: Depressive symptoms and mortality among persons with and without diabetes. Am. J. Epidemiol., 2005, 161, s. 652–660.
10. De Groot M., Anderson R., Freedman K. E. et al.: Association of depression and diabetes complications: a meta‑analysis. Psychosom. Med., 2001, s. 619–630.
11. Wannamethee, S. G., Shaper, A. G., Lennon, L., Morris, R. W.: Metabolic syndrome vs Framingham risk score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch. Intern. Med., 2005, 165, s. 2644-2650.
12. McCaffery, J. M., Niaura, R., Todaro, J. F. et al.: Depressive symptoms and metabolic risk in adult male twins enrolled in the National Heart, Lung, and Blod Institute Twin Study. Psychosom. Med., 2003, 65, s. 490–497.
13. Kinder, L. S., Carnethon, M. R., Palaniappan, L. P. et al.: Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom. Med., 2004, 66, s. 316–322.
14. Eaton, W. W: Epidemiologic evidence on the comorbidity of depression and diabetes. J. Psychosom. Res., 2002, 53, s. 903–906.
15. Talbot, F., Nouwen, A.: A review of the relationship between depression and diabetes in adults. Is there a link? Diabetes Care, 2000, 23, s. 1556–1562.
16. Lustman, P. J., Clouse, R. E.: Depression: a potentially modifiable risk factor for diabetes and its complications. Diabetes Spectrum, 2004, 17, s. 147–148.
17. Tschoner, A., Engl, J., Laimer, M. et al.: Metabolic side-effects of antipsychotic medication. Int. J. Clin. Pract., 2007, 61, s. 1356–1370.
18. Nasrallah, H. A.: A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology, 2003, 28, s. 83–96.
19. Snyder, E. E., Walts, B., Perusse, L. et al.: The human obesity gene map: the 2003 update. Obes Res., 2004, 12, s. 369–439.
20. Levinson, D. F.: The genetics of depression: a review. Biol. Psychiatry, 2006, 60, s. 84–92.
21. Bondy, B., Baghai, T. C., Zill P. et al.: Combined action of the ACE D-and G-protein beta3 T–allele in major depression: a possible link to cardiovascular disease? Mol. Psychiatry, 2002, 7, s. 1120–1126.
22. Baghai, T. C., Binder, E. B., Schule, C. et al.: Polymorphisms in the angiotensin–converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism. Mol. Psychiatry, 2006, 11, s. 1003–1015.
23. Chiba, M., Suzuki, S., Hinokio, Y. et al.: Tyrosine hydroxylase gene microsatellite polymorphism associated with insulin resistance in depressive disorder. Metabolism, 2000, 49, s. 1145–1149.
24. Timonen, M., Laakso, M., Jokelainen, J. et al.: Insulin resistance and depression: cross sectional study. Brit. Med. J., 2005, 330, s. 17–18.
25. Gillespie, C. F., Nemeroff, C. N.: Hypercortisolaemia and depression. Psychosom. Med., 2005, 67 (Suppl.1), s. S26–S28.
26. Kreier, F., Yilmaz, A., Kalsbeek, A. et al.: Hypothesis: shifting the equilibrium from activity to food leads to autonomic unbalance and the metabolic syndrome. Diabetes, 2003, 52, s. 2652–2656.
27. Furukawa, S., Fujita, T., Shimabukuro, M. et al.: Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest., 2004, 114, s. 1752–1761.
28. Sonnenberg, G. E., Krakower, G. R., Kissebah, A. H.: A novel pathway to the manifestation of metabolic syndrome. Obes. Res., 2004, 12, s. 180–186.
29. Wu, A., Ying, Z., Gomez-Pinilla, F.: The interplay between oxidative stress and brain–derived neurotrophic factor modulates the outcome of a saturated fat diet on synaptic plasticity and cognition. Eur. J. Neuroscience, 2004, 19, s. 1699–1707.
30. Kuloglu, M., Atmaca, M., Tezcan, E. et al.: Antioxidant enzyme activities and malondialdehyde levels in patients with obsessive-compulsive disorder. Neuropsychobiology, 2002, 46, s. 27–32.
31. Tsuboi, H., Shimoi, K., Kinae, N. et al.: Depressive symptoms are independently correlated with lipid peroxidation in a female population: comparison with vitamins and carotenoids. J Psychosom Res., 2004, 56, s. 53–58.
32. Bottiglieri, T., Laundy, M., Crellin, R. et al.: Homocysteine, folate, methylation and monoamine metabolism in depression. J. Neurol. Neurosurg. Psychiatry, 2000, 69, s. 228–232.
33. Bolander-Gouaille, C.: Focus on homocysteine and the vitamins involved in its metabolism. 2nd ed. Paris, Springer Verlag France, 2002, 262 s.
34. Mattson, M. P., Shea, T. B.: Folate and homocysteine metabolism in neural plasticity and neurodegenerative disorders. Trends Neurosci., 2003, 26, s. 137–148.
35. Bourre, J. M., Dumont, O., Durand, G.: Brain phospholipids as dietary source of (n-3) polyunsaturated fatty acids for nervous tissue in the rat. J. Neurochem., 1993, 60, s. 2018–2028.
36. Hibbeln, J. R.: Fish consumption and major depression. Lancet, 1998, 351, s. 1213.
37. Maes, M., Christophe, A., Delanghe, J. et al.: Lowered omega-3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res., 1999, 85, s. 175–291.
38. Peet, M., Murphy, B., Shay, J., Horrobin, D.: Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol. Psychiatry, 1998, 43, s. 315–319.
39. Mamalakis, G., Tornaritis, M., Kafatos, A.: Depression and adipose essential polyunsaturated fatty acids. Prostglandins Leukot. Essent. Fatty Acids, 2002, 67, s. 311–318.
40. Adams, P., Lawson, S., Ssanigorski, A., Sinclair, A.: Arachidonic acid to eicosapentaenoic acid ratio in blood correlates positively with clinical symptoms of depression. Lipids, 1996, 31, s. S157–S161.
41. Zimmer, L., Vancassel, S., Cantagrel, S. et al.: The dopamine mesocorticolimbic pathway is affected by deficiency in n–3 polyunsaturated fatty acids. Am. J. Clin. Nutr., 2002, 75, s. 662–667.
42. Hirashima, F., Parow, A. M., Stoll, A. L. et al.: Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am. J. Psychiatry, 2004, 161, s. 1922–1924.
43. Žák, A., Tvrzická, E., Zeman, M., Vecka, M.: Patofyziologie a klinický význam vícenenasycených mastných kyselin řady n-3. Čas. Lék. čes., 2005, 144 (Suppl. 1), s. 6–18.
44. Stoll, A. L., Severus, W. E., Freeman, M. P. et al.: Omega-3 fatty acids in bipolar disorder: a preliminary double-blind, placebo controlled trial. Arch. Gen. Psychiatry, 1999, 56, s. 407–412.
45. Nemets, B., Stahl, M., Belmaker, R.: Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am. J. Psychiatry, 2002, 150, s. 477–479.
46. Peet, M., Horrobin, D.: A dose-ranging study of the effects of ethyleicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch. Gen. Psychiatry, 2002, 59, s. 913–919.
47. Jacobs B. L., van Praag H. , Gage F. H.: Adult brain neurogenesis and psychiatry: a novel theory of depression. Mol. Psychiatry, 2000 5, 262–269
48. Beltz, B. S., Tlusty, M. F., Benton, J. L., Sandeman, D. C.: Omega-3 fatty acids upregulate adult neurogenesis. Neurosci Lett., 2007, 26, s. 154–158.
49. Wu, A, Ying, Z, Gomez-Pinilla, F.: Dietary omega-3 fatty acids normalize BDNF levels, reduce oxidative damage, and counteract learning disability after traumatic brain injury in rats. J. Neurotrauma, 2004, 21, s. 1457–1467.
50. Radloff, L. S. The CES-D Scale: A Self–Report Depression Scale for Research in the General Population. Applied Psychological Measurement, 1977, 1, s. 385–401.
Štítky
Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental HygienistČlánok vyšiel v časopise
Journal of Czech Physicians
- Advances in the Treatment of Myasthenia Gravis on the Horizon
- Spasmolytic Effect of Metamizole
- Metamizole at a Glance and in Practice – Effective Non-Opioid Analgesic for All Ages
- What Effect Can Be Expected from Limosilactobacillus reuteri in Mucositis and Peri-Implantitis?
- Metamizole in perioperative treatment in children under 14 years – results of a questionnaire survey from practice
Najčítanejšie v tomto čísle
- The Occurrence of Malignancies in Former Blood Donors
- Complications with the Pocket of Cardiostimulator
- Tracheal Intubation without Muscle Relaxant – the Impact of Different Sufentanil Doses on the Quality of Intubating Conditions: A Prospective Study
- Is the Extent of Present Examination of Blood Donors Sufficient? Malignancies in Active Blood Donors